TEK and neoplasm: Whether this finding could be due to a race-related difference in the tumor’s responsiveness to bevacizumab is deserving of further study to fully evaluate if ANGPT1, ANGPT2, TEK, FGF2, MMP9 and VEGFA are promising targets for future research.